These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26494271)

  • 1. Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer's Disease Pathology.
    Ulrich JD; Huynh TP; Holtzman DM
    Neuron; 2015 Oct; 88(2):237-9. PubMed ID: 26494271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of Widespread BBB Disruption in Alzheimer's Disease Models: Focus on Therapeutic Antibodies.
    Bien-Ly N; Boswell CA; Jeet S; Beach TG; Hoyte K; Luk W; Shihadeh V; Ulufatu S; Foreman O; Lu Y; DeVoss J; van der Brug M; Watts RJ
    Neuron; 2015 Oct; 88(2):289-97. PubMed ID: 26494278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Blood-brain barrier and Alzheimer's disease].
    Kuwahara H; Nishida Y; Yokota T
    Brain Nerve; 2013 Feb; 65(2):145-51. PubMed ID: 23399672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-brain barrier P-glycoprotein function in Alzheimer's disease.
    van Assema DM; Lubberink M; Bauer M; van der Flier WM; Schuit RC; Windhorst AD; Comans EF; Hoetjes NJ; Tolboom N; Langer O; Müller M; Scheltens P; Lammertsma AA; van Berckel BN
    Brain; 2012 Jan; 135(Pt 1):181-9. PubMed ID: 22120145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation.
    Boado RJ; Zhang Y; Zhang Y; Xia CF; Pardridge WM
    Bioconjug Chem; 2007; 18(2):447-55. PubMed ID: 17315944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.
    Pardridge WM
    Expert Opin Biol Ther; 2016 Dec; 16(12):1455-1468. PubMed ID: 27572805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.
    García-Barroso C; Ricobaraza A; Pascual-Lucas M; Unceta N; Rico AJ; Goicolea MA; Sallés J; Lanciego JL; Oyarzabal J; Franco R; Cuadrado-Tejedor M; García-Osta A
    Neuropharmacology; 2013 Jan; 64():114-23. PubMed ID: 22776546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracerebral GM-CSF contributes to transendothelial monocyte migration in APP/PS1 Alzheimer's disease mice.
    Shang S; Yang YM; Zhang H; Tian L; Jiang JS; Dong YB; Zhang K; Li B; Zhao WD; Fang WG; Chen YH
    J Cereb Blood Flow Metab; 2016 Nov; 36(11):1978-1991. PubMed ID: 27444968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrogen Sulfide Ameliorates Homocysteine-Induced Alzheimer's Disease-Like Pathology, Blood-Brain Barrier Disruption, and Synaptic Disorder.
    Kamat PK; Kyles P; Kalani A; Tyagi N
    Mol Neurobiol; 2016 May; 53(4):2451-2467. PubMed ID: 26019015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of the blood-brain barrier in Alzheimer's disease].
    Gosselet F; Candela P; Cecchelli R; Fenart L
    Med Sci (Paris); 2011 Nov; 27(11):987-92. PubMed ID: 22130026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine for the treatment of Alzheimer's disease.
    Gregori M; Masserini M; Mancini S
    Nanomedicine (Lond); 2015; 10(7):1203-18. PubMed ID: 25929574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice.
    Minogue AM; Jones RS; Kelly RJ; McDonald CL; Connor TJ; Lynch MA
    Neurobiol Aging; 2014 Jun; 35(6):1442-52. PubMed ID: 24439957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.
    Finke JM; Banks WA
    Hum Antibodies; 2017; 25(3-4):131-146. PubMed ID: 28035915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
    Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
    Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease.
    Yamazaki Y; Kanekiyo T
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High fat diet exacerbates Alzheimer's disease-related pathology in APPswe/PS1 mice.
    Thériault P; ElAli A; Rivest S
    Oncotarget; 2016 Oct; 7(42):67808-67827. PubMed ID: 27661129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is P-glycoprotein involved in amyloid-β elimination across the blood-brain barrier in Alzheimer's disease?
    Ohtsuki S; Ito S; Terasaki T
    Clin Pharmacol Ther; 2010 Oct; 88(4):443-5. PubMed ID: 20856239
    [No Abstract]   [Full Text] [Related]  

  • 19. The blood brain barrier in Alzheimer's disease.
    Chakraborty A; de Wit NM; van der Flier WM; de Vries HE
    Vascul Pharmacol; 2017 Feb; 89():12-18. PubMed ID: 27894893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing vascular disease could reduce Alzheimer's risk. Prevention and proper treatment can help prevent impaired blood flow to the brain.
    Duke Med Health News; 2013 Jan; 19(1):7. PubMed ID: 23762974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.